1. Home
  2. HUDI vs CMMB Comparison

HUDI vs CMMB Comparison

Compare HUDI & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Huadi International Group Co. Ltd.

HUDI

Huadi International Group Co. Ltd.

HOLD

Current Price

$0.42

Market Cap

10.0M

Sector

Industrials

ML Signal

HOLD

CMMB

Chemomab Therapeutics Ltd.

BUY

Current Price

$1.08

Market Cap

8.4M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
HUDI
CMMB
Founded
1998
2004
Country
China
Israel
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.0M
8.4M
IPO Year
2019
2023

Fundamental Metrics

Financial Performance
Metric
HUDI
CMMB
Price
$0.42
$1.08
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $15.00
AVG Volume (30 Days)
★ 322.5K
102.3K
Earning Date
06-29-2026
11-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 101.67
EPS
N/A
★ 0.04
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$27.00
Revenue Growth
N/A
N/A
52 Week Low
$0.46
$1.01
52 Week High
$1.67
$3.44

Technical Indicators

Market Signals
Indicator
HUDI
CMMB
Relative Strength Index (RSI) 15.42 24.22
Support Level N/A N/A
Resistance Level $0.84 $1.89
Average True Range (ATR) 0.08 0.12
MACD -0.02 -0.00
Stochastic Oscillator 20.01 5.36

Price Performance

Historical Comparison
HUDI
CMMB

About HUDI Huadi International Group Co. Ltd.

Huadi International Group Co Ltd is a manufacturer of industrial stainless steel seamless pipes and tubes products. Its products are used in the oil & gas transmission, chemistry engineering, food processing, medical devices, aeronautics and astronautics, boiler, irrigation works construction, automobile and naval architecture, paper mill and mechanical industries. Company generates revenue from Sales of steel piping products. Products are exported to the United States, Mexico, Thailand, Singapore, Argentina, Taiwan, India, the Philippines, UAE and Canada. Geographically, majority revenue is generated from China.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Share on Social Networks: